Selexipag (trade name: Uptravi) is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms. The drug can be used either as combination therapy with other blood-pressure ...
Oct 6, 2016
0
0
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high ...
Jun 20, 2016
0
86
Pioneering research conducted by the University of Sheffield is paving the way for new treatments which could benefit patients suffering from the fatal lung disease pulmonary arterial hypertension (PAH).
May 24, 2016
0
1238
In an article appearing in the May 10, 2016 issue of JAMA, Dinesh Khanna, M.D., of the University of Michigan Scleroderma Program, Ann Arbor, and colleagues evaluated the efficacy of the drug macitentan in reducing the number ...
May 10, 2016
0
3
Delegates at this year's Insigneo Showcase (May 5, 2016 at The Octagon Centre in Sheffield) will hear how in silico medicine—computer simulations of the human body and its disease processes—can help improve diagnosis ...
May 4, 2016
0
29
Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, ...
Apr 28, 2016
0
10
Swimmers and divers who are prone to a sudden and potentially life-threatening form of pulmonary edema in cold water could benefit from a simple and readily available dose of sildenafil, according to findings from a small ...
Feb 16, 2016
0
41
New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...
Jan 18, 2016
0
1
Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal ...
Dec 23, 2015
0
51
(HealthDay)—Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.
Dec 22, 2015
0
2
